Table 5 Sex-specific associations between oral bisphosphonates and colorectal cancer, Kaiser Permanente, Northern California, 1997–2011.

From: Oral bisphosphonates and colorectal cancer

 

OR

(95% CI)

Ever use oral bisphosphonates

 Females

0.84

(0.76, 0.92)

 Males

0.63

(0.47, 0.85)

 p interaction

0.0426

 

Defined Daily Dose

 Females

Never

Ref

 

<12 months

0.84

(0.73, 0.98)

>= 12 months

0.83

(0.74, 0.94)

 Males

Never

Ref

 

<12 months

0.71

(0.47, 1.08)

>= 12 months

0.56

(0.36, 0.86)

 p interaction (<12)

0.3194

 

 p interaction (> = 12)

0.0596

 
  1. Cases and controls were matched on sex, age at time of index date (+/−2 years), duration of membership prior to index date (+/−1 year), race, and region of residence.
  2. The adjusted model additionally included age, smoking, alcohol use, Charlson comorbidity index, use of NSAIDs, and previous lower endoscopy.
Back to article page